As pertussis returns to pre-COVID19 endemicity, vaccination remains our best ally against an evolving

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Epidemiological burden of pertussis in children in Asia: a review of 1990-2021 data and future projections.Translational pediatrics · 2026
   Article
2. Analysis of strategies China should adopt in response to global pertussis trends.Human vaccines & immunotherapeutics · 2025
   Article
3. Molecular epidemiology and genomic features of Bordetella pertussis in Tianjin, China, 2023.BMC microbiology · 2025
   Article
4. Molecular epidemiological characteristics of pertussis in a pediatric hospital in Jinan City, China, 2022 to 2024.Frontiers in public health · 2025
   Article
5. Whooping Cough: A Rising Risk for All Ages.Missouri medicine
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as